Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors

This trial is testing a combination of two targeted drugs — ulixertinib and palbociclib — to see if they can slow or stop the growth of advanced cancers, including pancreatic cancer and melanoma that have stopped responding to other treatments. **You may be eligible if...** - You are 18 or older - You have an advanced solid tumor that no longer responds to standard treatment - For the expanded group: you have metastatic pancreatic cancer or advanced melanoma that has already received at least one prior treatment - For melanoma specifically: your tumor has certain genetic mutations (in NRAS, KRAS, HRAS, or NF1 genes) and your cancer progressed after immune checkpoint therapy - You are well enough to perform basic daily activities (not bedridden) - Your life expectancy is at least 3 months - Your liver, kidneys, and blood counts are within acceptable ranges **You may NOT be eligible if...** - Your cancer has spread to your brain or spinal cord (unless stable) - You have serious heart problems, including a history of heart attacks or a dangerously irregular heartbeat - You are pregnant or breastfeeding - Your organ function (liver, kidney, bone marrow) is significantly impaired - You have had certain recent infections or uncontrolled illnesses Talk to your doctor to see if this trial is right for you.